HRP20170713T1 - Bispecifično anti-igf-1r i anti-erbb3 antitijelo - Google Patents

Bispecifično anti-igf-1r i anti-erbb3 antitijelo

Info

Publication number: HRP20170713T1
Authority: HR; Croatia
Prior art keywords: igf; erbb3 antibodies; bispecific; bispecific anti; erbb3
Prior art date: 2011-04-19

Application number

HRP20170713TT

Other languages

English (en)

Inventor

Jason BAUM

Bryan Johnson

Alexey Alexandrovich Lugovskoy

Lihui Xu

Neeraj Kohli

Jonathan Basil Fitzgerald

Sharlene Adams

Original Assignee

Merrimack Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-19

Filing date

2017-05-12

Publication date

2017-07-14

2017-05-12 Application filed by Merrimack Pharmaceuticals, Inc. filed Critical Merrimack Pharmaceuticals, Inc.

2017-07-14 Publication of HRP20170713T1 publication Critical patent/HRP20170713T1/hr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

HRP20170713TT 2011-04-19 2017-05-12 Bispecifično anti-igf-1r i anti-erbb3 antitijelo HRP20170713T1 (hr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201161477089P	2011-04-19	2011-04-19
US201161539297P	2011-09-26	2011-09-26
US201161558192P	2011-11-10	2011-11-10
US201261619244P	2012-04-02	2012-04-02
EP12773950.6A EP2699602B1 (en)	2011-04-19	2012-04-19	Bispecific anti-igf-1r and anti-erbb3 antibodies
PCT/US2012/034244 WO2012145507A2 (en)	2011-04-19	2012-04-19	Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies

Publications (1)

Publication Number	Publication Date
HRP20170713T1 true HRP20170713T1 (hr)	2017-07-14

Family

ID=47021510

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20170713TT HRP20170713T1 (hr)	2011-04-19	2017-05-12	Bispecifično anti-igf-1r i anti-erbb3 antitijelo

Country Status (20)

Country	Link
US (4)	US8476409B2 (hr)
EP (2)	EP3214096A3 (hr)
JP (2)	JP5588086B2 (hr)
KR (2)	KR20140138353A (hr)
CN (2)	CN105884900A (hr)
AU (2)	AU2012245491C1 (hr)
BR (1)	BR112013027021A2 (hr)
CA (1)	CA2833643A1 (hr)
DK (1)	DK2699602T3 (hr)
ES (1)	ES2625818T3 (hr)
HK (1)	HK1223383A1 (hr)
HR (1)	HRP20170713T1 (hr)
HU (1)	HUE034276T2 (hr)
IL (1)	IL228957A0 (hr)
MX (2)	MX346486B (hr)
PL (1)	PL2699602T3 (hr)
PT (1)	PT2699602T (hr)
SI (1)	SI2699602T1 (hr)
TW (1)	TWI631136B (hr)
WO (1)	WO2012145507A2 (hr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2129396T1 (sl)	2007-02-16	2013-12-31	Merrimack Pharmaceuticals, Inc.	Protitelesa proti ErbB3 in njihove uporabe
AU2010306774A1 (en) *	2009-10-14	2012-05-03	Merrimack Pharmaceuticals, Inc.	Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
EA201201186A1 (ru)	2010-03-11	2013-11-29	Мерримак Фармасьютикалс, Инк.	ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
CA2833643A1 (en)	2011-04-19	2012-10-26	Merrimack Pharmaceuticals, Inc.	Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
EP2833915A1 (en) *	2012-04-02	2015-02-11	Merrimack Pharmaceuticals, Inc.	Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
US9717724B2 (en)	2012-06-13	2017-08-01	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en)	2012-06-13	2016-06-02	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
CN104341504B (zh) *	2013-08-06	2017-10-24	百奥泰生物科技(广州)有限公司	双特异性抗体
EP3087394A2 (en)	2013-12-27	2016-11-02	Merrimack Pharmaceuticals, Inc.	Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
CA2975829A1 (en) *	2014-02-20	2015-09-03	Merrimack Pharmaceuticals, Inc.	Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
CN112851808A (zh) *	2014-04-25	2021-05-28	皮埃尔法布雷医药公司	Igf-1r抗体及其作为定位载体用于治疗癌症的用途
US11318131B2 (en)	2015-05-18	2022-05-03	Ipsen Biopharm Ltd.	Nanoliposomal irinotecan for use in treating small cell lung cancer
AU2016271138A1 (en) *	2015-05-29	2017-12-07	Merrimack Pharmaceuticals, Inc.	Combination cancer therapies
US10184006B2 (en)	2015-06-04	2019-01-22	Merrimack Pharmaceuticals, Inc.	Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017031442A1 (en)	2015-08-20	2017-02-23	Merrimack Pharmaceuticals, Inc.	Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
CA2993451A1 (en)	2015-08-21	2017-03-02	Ipsen Biopharm Ltd.	Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
BR122021024957B1 (pt)	2015-10-16	2023-12-12	Ipsen Biopharm Ltd	Processos de produção de uma composição de irinotecano lipossômico estabilizado em armazenamento
CN108602890A (zh)	2015-12-11	2018-09-28	瑞泽恩制药公司	用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
US20170233491A1 (en)	2016-01-19	2017-08-17	Merrimack Pharmaceuticals, Inc.	Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment
JP2019506863A (ja) *	2016-02-02	2019-03-14	カドモンコーポレイション，リミティドライアビリティカンパニー	Ｐｄ−ｌ１及びｋｄｒに対する二重結合タンパク質
US10723857B1 (en) *	2016-04-15	2020-07-28	United States Of America As Represented By The Administrator Of National Aeronautics And Space Administration	Polyimide aerogels with reduced shrinkage from isothermal aging
WO2018045256A1 (en) *	2016-09-02	2018-03-08	Merrimack Pharmaceuticals, Inc.	Combination of an erbb3 inhibitor, topoisomerase i inhibitor, and an alkylating agent to treat cancer
JP6825284B2 (ja) *	2016-09-21	2021-02-03	カシオ計算機株式会社	イメージ作成装置、イメージ作成方法、及び、プログラム
US11071726B2 (en)	2016-11-02	2021-07-27	Ipsen Biopharm Ltd.	Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
KR20240023201A (ko) *	2017-05-04	2024-02-20	악셀레론 파마 인코포레이티드	Tgf-베타 수용체 유형 ii 융합 단백질 및 이의 용도
CN107602702A (zh) *	2017-09-22	2018-01-19	生标（上海）医疗器械科技有限公司	一种同时靶向人p185和血管内皮生长因子的抗体及其应用
GB201804094D0 (en) *	2018-03-14	2018-04-25	Ultrahuman Thirteen Ltd	ERBB3 Binding agents
US10633458B2 (en)	2018-04-10	2020-04-28	Y-Biologics Inc.	Cell engaging binding molecules
CN113365663A (zh)	2018-08-30	2021-09-07	Hcw生物科技公司	单链嵌合多肽和其用途
US11672826B2 (en)	2018-08-30	2023-06-13	HCW Biologics, Inc.	Methods of treating aging-related disorders
WO2020047299A1 (en)	2018-08-30	2020-03-05	HCW Biologics, Inc.	Multi-chain chimeric polypeptides and uses thereof
CN114269903A (zh)	2019-06-21	2022-04-01	Hcw生物科技公司	多链嵌合多肽和其用途
JP2023519106A (ja)	2020-02-11	2023-05-10	エイチシーダブリューバイオロジックスインコーポレイテッド	クロマトグラフィー樹脂およびその使用
CN115380045A (zh)	2020-02-11	2022-11-22	Hcw生物科技公司	激活调节性t细胞的方法
CA3169231A1 (en)	2020-02-11	2021-08-19	HCW Biologics, Inc.	Methods of treating age-related and inflammatory diseases
CN113512116B (zh) *	2020-04-10	2022-09-20	苏州普乐康医药科技有限公司	一种抗igf-1r抗体及其应用
CA3181417A1 (en)	2020-04-29	2021-11-04	HCW Biologics, Inc.	Anti-cd26 proteins and uses thereof
WO2021247003A1 (en)	2020-06-01	2021-12-09	HCW Biologics, Inc.	Methods of treating aging-related disorders
CA3184756A1 (en)	2020-06-01	2021-12-09	HCW Biologics, Inc.	Methods of treating aging-related disorders
WO2023030311A1 (zh) *	2021-08-31	2023-03-09	上海医药集团股份有限公司	靶向Siglec15的抗原结合蛋白及其用途
WO2023168363A1 (en)	2022-03-02	2023-09-07	HCW Biologics, Inc.	Method of treating pancreatic cancer

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988007089A1 (en)	1987-03-18	1988-09-22	Medical Research Council	Altered antibodies
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
US5183884A (en)	1989-12-01	1993-02-02	United States Of America	Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0896586B2 (en)	1996-03-27	2015-05-20	Genentech, Inc.	ErbB3 ANTIBODIES
US20020062010A1 (en)	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
PT1071700E (pt)	1998-04-20	2010-04-23	Glycart Biotechnology Ag	Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
PT1914244E (pt)	1999-04-09	2013-07-26	Kyowa Hakko Kirin Co Ltd	Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
JP4668498B2 (ja)	1999-10-19	2011-04-13	協和発酵キリン株式会社	ポリペプチドの製造方法
AU2001294175A1 (en)	2000-10-06	2002-04-22	Kyowa Hakko Kogyo Co. Ltd.	Method of purifying antibody
CA2785941C (en)	2000-10-06	2017-01-10	Kyowa Hakko Kirin Co., Ltd.	Antibody composition-producing cell
HUP0302525A2 (hu) *	2001-01-05	2003-10-28	Abgenix, Inc.	Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
WO2002079255A1 (en)	2001-04-02	2002-10-10	Idec Pharmaceuticals Corporation	RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
EP1283053A1 (en)	2001-08-09	2003-02-12	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Inhibitors of HER3 activity
EP1443961B1 (en)	2001-10-25	2009-05-06	Genentech, Inc.	Glycoprotein compositions
US7332585B2 (en)	2002-04-05	2008-02-19	The Regents Of The California University	Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en)	2002-04-05	2008-02-19	The Regents Of The University Of California	Bispecific single chain Fv antibody molecules and methods of use thereof
EP1622942B1 (en) *	2003-05-01	2014-11-19	ImClone LLC	Fully human antibodies directed against the human insulin-like growth factor-1 receptor
CN1871259A (zh)	2003-08-22	2006-11-29	比奥根艾迪克Ma公司	具有改变的效应物功能的经改进的抗体和制备它的方法
EP1697415A1 (en)	2003-11-12	2006-09-06	Biogen Idec MA Inc.	NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005063815A2 (en)	2003-11-12	2005-07-14	Biogen Idec Ma Inc.	Fcϝ receptor-binding polypeptide variants and methods related thereto
BRPI0611445A2 (pt)	2005-05-09	2010-09-08	Glycart Biotechnology Ag	molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
WO2007109254A2 (en) *	2006-03-17	2007-09-27	Biogen Idec Ma Inc.	Stabilized polypeptide compositions
EP2091975A4 (en) *	2006-11-21	2013-05-22	Univ California	ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE
SI2129396T1 (sl)	2007-02-16	2013-12-31	Merrimack Pharmaceuticals, Inc.	Protitelesa proti ErbB3 in njihove uporabe
MX2009009379A (es) *	2007-03-02	2009-09-14	Amgen Inc	Metodos y composiciones para tratar enfermedades tumorales.
KR20100052545A (ko) *	2007-08-28	2010-05-19	바이오겐 아이덱 엠에이 인코포레이티드	Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
CA2721093A1 (en)	2008-04-11	2009-10-15	Merrimack Pharmaceuticals, Inc.	Human serum albumin linkers and conjugates thereof
US8623592B2 (en)	2008-08-15	2014-01-07	Merrimack Pharmaceuticals, Inc.	Methods and systems for predicting response of cells to a therapeutic agent
CA2759792A1 (en)	2009-04-29	2010-11-04	Trellis Bioscience, Inc.	Improved antibodies immunoreactive with heregulin-coupled her3
RU2570633C2 (ru) *	2009-05-27	2015-12-10	Ф.Хоффманн-Ля Рош Аг	Три- или тетраспецифические антитела
UY32808A (es) *	2009-07-29	2011-02-28	Abbott Lab	Inmunoglobulinas como dominio variable dual y usos de las mismas
CA2771744A1 (en)	2009-08-21	2011-02-24	Merrimack Pharmaceuticals, Inc.	Antibodies against the ectodomain of erbb3 and uses thereof
IN2012DN02737A (hr)	2009-09-01	2015-09-11	Abbott Lab
AU2010306774A1 (en) *	2009-10-14	2012-05-03	Merrimack Pharmaceuticals, Inc.	Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
HUE029026T2 (en)	2009-12-22	2017-01-30	Roche Glycart Ag	Anti-HER3 antibodies and their applications
BR112012025730B1 (pt)	2010-04-09	2020-12-08	Aveo Pharmaceuticals, Inc	anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
EA036314B1 (ru) *	2010-08-20	2020-10-26	Новартис Аг	Выделенные антитела к рецептору эпидермального фактора роста-3 (her3) и их фрагменты, фармацевтическая композиция, содержащая эти антитела и фрагменты, и их применение для лечения рака
CA2833643A1 (en)	2011-04-19	2012-10-26	Merrimack Pharmaceuticals, Inc.	Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
EP2833915A1 (en) *	2012-04-02	2015-02-11	Merrimack Pharmaceuticals, Inc.	Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
CA2975829A1 (en) *	2014-02-20	2015-09-03	Merrimack Pharmaceuticals, Inc.	Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
US20170233491A1 (en) *	2016-01-19	2017-08-17	Merrimack Pharmaceuticals, Inc.	Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment

2012
- 2012-04-19 CA CA2833643A patent/CA2833643A1/en not_active Abandoned
- 2012-04-19 JP JP2014506549A patent/JP5588086B2/ja not_active Expired - Fee Related
- 2012-04-19 SI SI201230955A patent/SI2699602T1/sl unknown
- 2012-04-19 KR KR1020147031817A patent/KR20140138353A/ko not_active Application Discontinuation
- 2012-04-19 WO PCT/US2012/034244 patent/WO2012145507A2/en active Search and Examination
- 2012-04-19 MX MX2016000234A patent/MX346486B/es unknown
- 2012-04-19 KR KR1020137030562A patent/KR101517320B1/ko not_active IP Right Cessation
- 2012-04-19 PT PT127739506T patent/PT2699602T/pt unknown
- 2012-04-19 DK DK12773950.6T patent/DK2699602T3/en active
- 2012-04-19 EP EP17158234.9A patent/EP3214096A3/en not_active Withdrawn
- 2012-04-19 HU HUE12773950A patent/HUE034276T2/en unknown
- 2012-04-19 CN CN201510472421.9A patent/CN105884900A/zh active Pending
- 2012-04-19 US US13/451,135 patent/US8476409B2/en active Active
- 2012-04-19 MX MX2013012201A patent/MX336197B/es unknown
- 2012-04-19 CN CN201280028639.XA patent/CN103703026B/zh not_active Expired - Fee Related
- 2012-04-19 AU AU2012245491A patent/AU2012245491C1/en not_active Ceased
- 2012-04-19 EP EP12773950.6A patent/EP2699602B1/en active Active
- 2012-04-19 TW TW101114063A patent/TWI631136B/zh not_active IP Right Cessation
- 2012-04-19 PL PL12773950T patent/PL2699602T3/pl unknown
- 2012-04-19 BR BR112013027021A patent/BR112013027021A2/pt not_active Application Discontinuation
- 2012-04-19 ES ES12773950.6T patent/ES2625818T3/es active Active
2013
- 2013-02-27 US US13/778,984 patent/US9556274B2/en not_active Expired - Fee Related
- 2013-10-17 IL IL228957A patent/IL228957A0/en unknown
2014
- 2014-04-09 JP JP2014080445A patent/JP6214453B2/ja not_active Expired - Fee Related
2015
- 2015-09-17 US US14/857,344 patent/US9527914B2/en not_active Expired - Fee Related
2016
- 2016-08-26 US US15/248,562 patent/US9938346B2/en active Active
- 2016-10-10 HK HK16111680.4A patent/HK1223383A1/zh unknown
2017
- 2017-05-12 HR HRP20170713TT patent/HRP20170713T1/hr unknown
- 2017-08-16 AU AU2017216490A patent/AU2017216490A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20160137738A1 (en)	2016-05-19
MX336197B (es)	2016-01-11
TWI631136B (zh)	2018-08-01
DK2699602T3 (en)	2017-06-06
EP3214096A3 (en)	2017-10-18
CN103703026B (zh)	2015-08-26
US9938346B2 (en)	2018-04-10
MX346486B (es)	2017-03-22
EP2699602B1 (en)	2017-03-01
ES2625818T3 (es)	2017-07-20
KR20140033050A (ko)	2014-03-17
US9556274B2 (en)	2017-01-31
AU2012245491C1 (en)	2017-12-21
WO2012145507A3 (en)	2013-11-07
AU2012245491A1 (en)	2013-10-31
JP6214453B2 (ja)	2017-10-18
US9527914B2 (en)	2016-12-27
HK1223383A1 (zh)	2017-07-28
US20160122438A9 (en)	2016-05-05
KR101517320B1 (ko)	2015-05-28
CA2833643A1 (en)	2012-10-26
EP3214096A2 (en)	2017-09-06
EP2699602A2 (en)	2014-02-26
SI2699602T1 (sl)	2017-06-30
MX2013012201A (es)	2014-05-28
US8476409B2 (en)	2013-07-02
AU2017216490A1 (en)	2017-08-31
JP2014158485A (ja)	2014-09-04
US20120269812A1 (en)	2012-10-25
WO2012145507A2 (en)	2012-10-26
CN105884900A (zh)	2016-08-24
HUE034276T2 (en)	2018-02-28
US20130236459A1 (en)	2013-09-12
PL2699602T3 (pl)	2017-11-30
US20170051063A1 (en)	2017-02-23
BR112013027021A2 (pt)	2016-11-29
PT2699602T (pt)	2017-06-12
AU2012245491B2 (en)	2017-08-17
IL228957A0 (en)	2013-12-31
CN103703026A (zh)	2014-04-02
TW201302790A (zh)	2013-01-16
JP5588086B2 (ja)	2014-09-10
KR20140138353A (ko)	2014-12-03
JP2014513950A (ja)	2014-06-19

Publication	Publication Date	Title
HRP20170713T1 (hr)	2017-07-14	Bispecifično anti-igf-1r i anti-erbb3 antitijelo
HUS2100034I1 (hu)	2021-10-28	ANGPTL3-ellenes antitestek és alkalmazásaik
IL281250A (en)	2021-04-29	Anti-PHF-tau antibodies and uses thereof
IL251697A0 (en)	2017-06-29	Antibodies against 3erbb and their uses
HK1202563A1 (en)	2015-10-02	Sequence symmetric modified igg4 bispecific antibodies igg4
EP2922874A4 (en)	2016-10-19	BISPECIFIC ANTIBODIES
HK1200853A1 (en)	2015-08-14	Meditopes and meditope-binding antibodies and uses thereof
IL228802A0 (en)	2013-12-31	Bispecific antibodies against 2her and 3cd
HK1202565A1 (en)	2015-10-02	Sequence symmetric modified igg4 bispecific antibodies igg4
HK1182625A1 (en)	2013-12-06	Bispecific antibodies
EP2748199A4 (en)	2015-06-17	ANTI-OX40 ANTIBODIES AND METHOD FOR THEIR USE
EP2756094A4 (en)	2015-05-06	ANTI-B7-H4 ANTIBODIES AND USES THEREOF
EP2722343A4 (en)	2014-12-17	ANTI-ERBB3 ANTIBODIES
ZA201407272B (en)	2016-11-30	Anti-baff-anti-il-17 bispecific antibodies
HK1199842A1 (en)	2015-07-24	Anti-siglec-15 antibodies and uses thereof -15